淫羊藿苷抗骨质疏松:从分子机制到生物医学应用的研究进展综述
本文系统综述淫羊藿苷(ICA)在骨质疏松(OP)治疗中的剂型、动物模型疗效及分子机制。按PRISMA指南检索Web of Science核心合集,最终纳入182篇文献分析。ICA通过创新递送系统增强靶向疗效,在多种OP模型中改善骨微结构和骨密度,机制涉及促成骨、抑破骨及多靶点调控。
要点
- ICA在去卵巢、糖皮质激素诱导、衰老及糖尿病OP模型中均改善骨微结构与骨密度。
- ICA通过促进成骨、抑制破骨生成发挥双向调控,并涉及自噬、抗炎、铁过载及氧化应激。
- 创新递送系统(中药制剂与先进生物材料)可增强ICA的靶向疗效。
核心结论
- 淫羊藿苷(ICA)通过多机制干预策略及先进递送系统,是治疗骨质疏松(OP)天然、安全、有效的候选药物,支持其进一步临床转化。
研究设计与样本
- 本综述按PRISMA指南系统检索Web of Science核心合集,最终纳入182篇出版物进行深入分析。
主要发现
- 在去卵巢、糖皮质激素诱导、衰老及糖尿病OP模型中,ICA一致改善骨微结构和骨密度。
- ICA通过创新递送系统(包括中药制剂和先进生物材料)增强靶向疗效。
- 机制上,ICA促进成骨并抑制破骨生成,同时涉及自噬调控、抗炎、减轻铁过载和降低氧化应激等多靶点作用。
临床怎么用
- ICA可作为OP治疗的天然候选药物,但临床转化需进一步研究;当前证据主要来自动物模型和递送系统研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis (OP) is characterized by decreased bone mass and deterioration of bone microstructure, significantly increasing fracture risk. Icariin (ICA), a natural compound, has demonstrated efficacy in improving bone microstructure and bone mineral density (BMD) across multiple OP models, with its targeting efficacy enhanced through innovative drug delivery systems. This review systematically summarizes recent advances in ICA research, focusing on its application dosage forms, therapeutic performance in various animal models, and underlying molecular mechanisms. In order to ensure a comprehensive and reliable report, we conducted a systematic search in the core collection of web of science according to PRISMA guidelines, and finally included 182 publications for in-depth analysis. ICA's therapeutic efficacy is enhanced through innovative delivery systems, including traditional Chinese medicine formulations and advanced biomaterials. Studies across postmenopausal, glucocorticoid-induced, aging, and diabetic OP models consistently demonstrate ICA's ability to improve bone microarchitecture and BMD. Mechanistically, ICA exerts dual-regulation effects by promoting osteogenesis while inhibiting osteoclastogenesis, coupled with multi-target actions involving autophagy regulation, anti-inflammatory effects, iron overload mitigation, and oxidative stress reduction. In conclusion, ICA's comprehensive and multi-mechanistic intervention strategy, augmented by advanced delivery systems, presents a natural, safe, and efficacious candidate for OP treatment. This review synthesizes critical advances from molecular mechanisms to biomedical applications, supporting further clinical translation of ICA-based therapies.
引用
- Fu B, Yu S, Chen S, et al. Icariin against osteoporosis: a review of advances in molecular mechanisms to biomedical applications. Front Pharmacol. 2025. PMID: 41378223. doi:10.3389/fphar.2025.1688847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。